But nothing is known yet about the clinical utility of the recently identified susceptibility factors, whether they are class one or class two. While these novel susceptibility factors have been shown to be significantly associated with an increased relative breast cancer risk, the statistical significance does not imply clinical utility for preventive management and therapy of breast cancer – at least not yet.